Markets:

Overview

News

Currencies

International

Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.54 +0.50 (+2.93%)

Streaming Delayed Price Updated: 11:42 AM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 Next >

3 Stocks Under $50 We’re Skeptical Of

August 18, 2026

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Via StockStory

Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 ↗

August 13, 2026

Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months.

Via The Motley Fool

Topics Regulatory Compliance

Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength.

Via The Motley Fool

Topics Earnings

Bausch + Lomb Corp (NYSE:BLCO) Beats Q1 Estimates, Raises Full-Year Guidance ↗

April 29, 2026

Via Chartmill

Bausch + Lomb Q2 Earnings Call Highlights ↗

July 29, 2026

Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook....

Via MarketBeat

Topics Earnings

Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations

July 29, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil...

Via StockStory

Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect

July 27, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Bausch + Lomb beat analysts’ ...

Via StockStory

Topics Artificial Intelligence

3 Reasons to Avoid BLCO and 1 Stock to Buy Instead

July 22, 2026

Over the past six months, Bausch + Lomb’s stock price fell to $15.99. Shareholders have lost 7% of their capital, which is disappointing considering the S&P ...

Via StockStory

Topics Stocks

Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today

July 10, 2026

What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma t...

Via StockStory

Topics Artificial Intelligence Economy Initial Public Offering

July 06, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

3 Small-Cap Stocks We Steer Clear Of

June 30, 2026

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Via StockStory

1 Stock Under $50 to Own for Decades and 2 We Turn Down

June 25, 2026

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline...

Via StockStory

Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest

May 19, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty...

Via StockStory

3 Profitable Stocks We’re Skeptical Of

May 18, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript ↗

April 30, 2026

Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript

Via The Motley Fool

Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026

April 29, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) announced better-than-expected revenue in Q1 CY2026, with sales up 9.4% year on year to $1.24 billion. The company’...

Via StockStory

Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For

April 27, 2026

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before the bell. Here’s what to expect. Bausch + Lomb beat analysts’ reve...

Via StockStory

Bausch Lomb BLCO Q2 2025 Earnings Transcript ↗

April 21, 2026

Bausch Lomb BLCO Q2 2025 Earnings Transcript

Via The Motley Fool

Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript ↗

April 21, 2026

Bausch + Lomb (BLCO) Q3 2025 Earnings Transcript

Via The Motley Fool

Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript ↗

April 21, 2026

Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript

Via The Motley Fool

Topics Initial Public Offering

3 Cash-Burning Stocks We Keep Off Our Radar

April 10, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Via StockStory

Topics Bankruptcy

1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off

April 08, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...

Via StockStory

Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks

April 01, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and...

Via StockStory

3 Reasons BLCO is Risky and 1 Stock to Buy Instead

March 26, 2026

Even during a down period for the markets, Bausch + Lomb has gone against the grain, climbing to $16.01. Its shares have yielded a 10.4% return over the last...

Via StockStory

Topics Bankruptcy

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story ↗

March 24, 2026

Bausch + Lomb, a global leader in eye health products and surgical devices, reported a recent insider buy amid ongoing sector activity.

Via The Motley Fool

Topics Regulatory Compliance

Billboard Giant Posts $1.6 Billion Revenue as $20.5 Million Bet Makes It a Top Portfolio Holding ↗

March 12, 2026

This outdoor advertising firm operates a vast network of displays across the Americas and Europe, serving a diverse global client base.

Via The Motley Fool

Topics Regulatory Compliance

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position ↗

March 12, 2026

Bausch + Lomb provides eye health products and surgical devices globally, serving both healthcare professionals and consumers.

Via The Motley Fool

Topics Regulatory Compliance

Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know

March 06, 2026

Via StockStory

Topics Earnings Economy

2 Profitable Stocks Worth Investigating and 1 We Ignore

March 04, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bausch + Lomb Corporation Common Shares (NY:BLCO)

Headline News about Bausch + Lomb Corporation Common Shares

Starting at /week.